Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
University of Miami Hospital, Miami, Florida The Johns Hopkins Hospital, Baltimore, Maryland University of Michigan Hospital, Ann Arbor, Michigan United Kingdom
Manchester University NHS Foundation Trust, Manchester, Greater Manchester Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester, Greater Manchester Leicester General Hospital, Leicester, Leicestershire Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire Southmead Hospital, Bristol Cardiff and Vale University Health Board, Cardiff Royal Infirmary of Edinburgh Clinical Research Facility, Edinburgh The Royal London Hospital, London